Insuline gecombineerd met een DPP-4-remmer: een nieuwe behandeloptie bij type 2 diabetes mellitus

被引:0
|
作者
Stijn A. Peeters
Rutgert Bianchi
Jacqueline Buijs
机构
[1] Afdeling interne geneeskunde,AIOS interne geneeskunde, Atrium Medisch Centrum Heerlen
[2] Internist-endocrinoloog,undefined
[3] Atrium Medisch Centrum Heerlen,undefined
[4] Internist,undefined
[5] Atrium Medisch Centrum Heerlen,undefined
关键词
D O I
10.1007/s12467-014-0024-3
中图分类号
学科分类号
摘要
De behandeling van patiënten met type 2 diabetes mellitus is complex, mede vanwege het feit dat het gaat om het vinden van een goede balans tussen strikte glucoseregulatie en het voorkomen van hypoglycemieën. Nieuwe geneesmiddelen, zoals GLP-1-analogen en DPP-4-remmers, zijn recent geïntroduceerd voor de behandeling van type 2 diabetes mellitus, maar hun exacte plaats in de behandelprotocollen is nog niet duidelijk in Nederland.
引用
收藏
页码:104 / 109
页数:5
相关论文
共 50 条
  • [41] DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson’s disease: a mutual relationship
    Mohammed Alrouji
    Hayder M. Al-kuraishy
    Ali K. Al-buhadily
    Ali I. Al-Gareeb
    Engy Elekhnawy
    Gaber El-Saber Batiha
    Pharmacological Reports, 2023, 75 : 923 - 936
  • [42] DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson's disease: a mutual relationship
    Alrouji, Mohammed
    Al-kuraishy, Hayder M.
    Al-buhadily, Ali K.
    Al-Gareeb, Ali I.
    Elekhnawy, Engy
    Batiha, Gaber El-Saber
    PHARMACOLOGICAL REPORTS, 2023, 75 (04) : 923 - 936
  • [43] Efficacy of DPP-4 inhibitors and predictive factor for the treatment in patients with type 2 diabetes mellitus
    Hahm, J. R.
    Lee, S. M.
    Jung, T. S.
    Jung, J. H.
    Chung, S. I.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 : 103 - 103
  • [44] Clinical effectiveness of switching between DPP-4 inhibitors in patients with type 2 diabetes mellitus
    Suzuki, Yuta
    Tanaka, Akihiro
    Tanaka, Mamoru
    Hidaka, Noriaki
    Miyake, Teruki
    Matsuura, Bunzo
    Hiasa, Yoichi
    Araki, Hiroaki
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (09) : 474 - 477
  • [45] Saxagliptin, a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus: novel aspects
    Pedrianes Martin, P.
    de Pablos Velasco, P. L.
    AVANCES EN DIABETOLOGIA, 2010, 26 (06): : 446 - 448
  • [46] The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
    Ametov, A. S.
    Karpova, E., V
    DIABETES MELLITUS, 2011, 14 (04): : 55 - 59
  • [47] The Effect of DPP-4 Inhibitor, Alogliptin, on Bone Metabolism in Patients With Type 2 Diabetes Mellitus
    Yamauchi, Yuichiro
    Tunekawa, Shin
    Seino, Yusuke
    Uenishi, Eita
    Okawa, Tetuji
    Fujiya, Atushi
    Ishikawa, Kouta
    Ogata, Hidetada
    Iida, Atushi
    Banno, Ryoichi
    Arima, Hiroshi
    Hamada, Yoji
    Oiso, Yutaka
    DIABETES, 2013, 62 : A276 - A277
  • [48] Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
    Sim, A. Young
    Barua, Sumit
    Kim, Jong Youl
    Lee, Yong-ho
    Lee, Jong Eun
    FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [49] NATIONAL COUNCIL OF EXPERTS: THE PLACE OF DPP-4 INHIBITORS IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Shestakova, Marina V.
    Vagapova, Gulnar R.
    Vikulova, Olga K.
    Galstyan, Gagik R.
    Demidova, Tatiana Y.
    Dudinskaya, Ekaterina N.
    Kiseleva, Tatiana P.
    Mkrtumyan, Ashot M.
    Petunina, Nina A.
    Tkacheva, Olga N.
    Fadeev, Valentin V.
    Khalimov, Yuriy S.
    Shestakova, Ekaterina A.
    DIABETES MELLITUS, 2023, 26 (06): : 619 - 625
  • [50] Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
    不详
    DIABETES MELLITUS, 2012, 15 (02): : 103 - 104